• ʻO Dabrafenib

    ʻO Dabrafenib

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    ʻO Dabrafenib      
  • Aprocitentan

    Aprocitentan

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Aprocitentan      
  • Etrasimod

    Etrasimod

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Etrasimod Ulceratuve Colitis(UC) Arena(Pfizer) Mar.05,2030
  • Tirzepatide

    Tirzepatide

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Tirzepatide ʻO ka maʻi diabetes type 2, hoʻemi i ke kaumaha Eli Lilly Jan.05,2036
  • Semaglutide

    Semaglutide

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Semaglutide ʻO ka maʻi diabetes type2, hoʻemi i ke kaumaha Novo Nordisk Dek.05,2031
  • Oteseconazole

    Oteseconazole

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Oteseconazole E hoemi i ka helu o ka

    candidiasis vulvovaginal hou

    MycoviaPharmaceuticals Apr.22,2031
  • Finerenone

    Finerenone

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Finerenone ʻO Nephropathy maʻi maʻi Bayer Apr.12,2029
  • Vibegron

    Vibegron

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Vibegron OAB Urovant Dek.01,2030
  • Capivasertib

    Capivasertib

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Capivasertib ka maʻi ʻaʻai umauma AstraZeneca Mar.10.2030
  • Resmetirom

    Resmetirom

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Resmetirom NASH ʻO Roche Sep.12,2026
  • ʻO Darolutamide

    ʻO Darolutamide

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    ʻO Darolutamide lapaʻau maʻi maʻi prostatic Bayer Mar. 25,2033
  • Upadacitinib

    Upadacitinib

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Upadacitinib ʻO ka Dermatitis Atopic ABBVIE INC Dek.01,2030
123456Aʻe >>> ʻAoʻao 1 / 6